[go: up one dir, main page]

WO2005113765A3 - Methods of activation of sulfatases and methods and compositions of using the same - Google Patents

Methods of activation of sulfatases and methods and compositions of using the same Download PDF

Info

Publication number
WO2005113765A3
WO2005113765A3 PCT/US2005/014097 US2005014097W WO2005113765A3 WO 2005113765 A3 WO2005113765 A3 WO 2005113765A3 US 2005014097 W US2005014097 W US 2005014097W WO 2005113765 A3 WO2005113765 A3 WO 2005113765A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
sulfatases
activation
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/014097
Other languages
French (fr)
Other versions
WO2005113765A2 (en
Inventor
Todd Zankel
Gary Nicholas Zecherle
Christopher M Starr
Teresa Margaret Christianson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomarin Pharmaceutical Inc
Original Assignee
Biomarin Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharmaceutical Inc filed Critical Biomarin Pharmaceutical Inc
Publication of WO2005113765A2 publication Critical patent/WO2005113765A2/en
Publication of WO2005113765A3 publication Critical patent/WO2005113765A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

The present invention is directed to a methods of producing activated sulfatase proteins. Methods and compositions of using such activated compositions in the intervention of a variety of disorders are disclosed.
PCT/US2005/014097 2004-05-06 2005-04-25 Methods of activation of sulfatases and methods and compositions of using the same Ceased WO2005113765A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56854404P 2004-05-06 2004-05-06
US60/568,544 2004-05-06

Publications (2)

Publication Number Publication Date
WO2005113765A2 WO2005113765A2 (en) 2005-12-01
WO2005113765A3 true WO2005113765A3 (en) 2006-01-12

Family

ID=35428930

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/014097 Ceased WO2005113765A2 (en) 2004-05-06 2005-04-25 Methods of activation of sulfatases and methods and compositions of using the same

Country Status (1)

Country Link
WO (1) WO2005113765A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104540517A (en) * 2012-06-29 2015-04-22 夏尔人类遗传性治疗公司 Cells for producing recombinant iduronate-2-sulfatase

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7985783B2 (en) * 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
US7722865B2 (en) 2008-01-18 2010-05-25 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
WO2009091994A2 (en) 2008-01-18 2009-07-23 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
US8729232B2 (en) 2008-03-27 2014-05-20 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
US20120180148A1 (en) * 2011-01-07 2012-07-12 Jin Thong-Gyu Transgenic mouse model for developing enzyme replacement therapy for iduronate-2-sulfatase deficiency syndrome
KR101158673B1 (en) * 2011-06-24 2012-07-03 주식회사 지씨바이오 Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
WO2013148323A1 (en) * 2012-03-30 2013-10-03 Shire Human Genetic Therapies Methods of analyzing and preparing protein compositions
EP2830642B1 (en) * 2012-03-30 2019-08-28 Shire Human Genetic Therapies, Inc. Subcutaneous administration of iduronate- 2-sulfatase
KR101380740B1 (en) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 Purification of iduronate-2-sulfatase
US20140004097A1 (en) 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
MX2018005785A (en) 2015-11-09 2019-04-04 Scherer Technologies Llc R P Anti-cd22 antibody-maytansine conjugates and methods of use thereof.
US11208632B2 (en) 2016-04-26 2021-12-28 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHRISTIANSON T. ET AL.: "Overexpression of inactive arysulphatase mutants and in vitro activation by light-dependent oxidation with vanadate.", BIOCHEM. J., vol. 382, September 2004 (2004-09-01), pages 581 - 587, XP002992392 *
ZALK P. ET AL.: "ATP-binding sites in brain p97/VCP (valosin-containing protein), a multifunctional AAA ATPase.", BIOCHEM J., vol. 374, May 2003 (2003-05-01), pages 473 - 480, XP002992393 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104540517A (en) * 2012-06-29 2015-04-22 夏尔人类遗传性治疗公司 Cells for producing recombinant iduronate-2-sulfatase

Also Published As

Publication number Publication date
WO2005113765A2 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
WO2005105780A3 (en) Compositions useful as inhibitors of rock and other protein kinases
AU2003202259A1 (en) Lipid compositions, production thereof and of esters
WO2005113765A3 (en) Methods of activation of sulfatases and methods and compositions of using the same
WO2005028475A3 (en) Compositions useful as inhibitors of protein kinases
WO2004091572A3 (en) Cochleate compositions directed against expression of proteins
WO2006050477A3 (en) Anti-microbial compositions and methods of making and using the same
WO2004080406A3 (en) Therapeutic compositions
WO2005110396A3 (en) Nitrated lipids and methods of making and using thereof
EP2270037A3 (en) Hasylated Factor IX
WO2007067504A3 (en) Lactam compounds and methods of using the same
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
WO2007125105A3 (en) Benzamide glucokinase activators
AU2006305225A8 (en) Wig and method of producing the same
WO2006063055A3 (en) Enzyme conjugates for use as detoxifying agents
AUPS017702A0 (en) Methods and compositions for the treatment of asthma and related disorders
EP2305821A3 (en) Protease variants
EP1613269A4 (en) Compositions, methods and kits relating to her-2 cleavage
WO2007101106A3 (en) Compositions and methods for modulating hemostasis using variant forms of activated factor v
WO2007067784A3 (en) Liposomal compositions
WO2004030634A3 (en) Therapeutic compositions
WO2007025146A3 (en) Balsalazide formulations and manufacture and use thereof
AU2001268232A1 (en) Compositions, methods, and kits relating to resistin-like molecules
WO2004073686A3 (en) Menthol solutions of drugs
WO2006063031A3 (en) Allelic variants of human factor viii
WO2007064304A8 (en) Biocompatible composition and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase